ATE538782T1 - Modifizierte aminosaeure 5-cnac zur hemmung der thrombozytenaggregation - Google Patents

Modifizierte aminosaeure 5-cnac zur hemmung der thrombozytenaggregation

Info

Publication number
ATE538782T1
ATE538782T1 AT03763878T AT03763878T ATE538782T1 AT E538782 T1 ATE538782 T1 AT E538782T1 AT 03763878 T AT03763878 T AT 03763878T AT 03763878 T AT03763878 T AT 03763878T AT E538782 T1 ATE538782 T1 AT E538782T1
Authority
AT
Austria
Prior art keywords
modified amino
cnac
amino acids
thrombocyte aggregation
inhibiting
Prior art date
Application number
AT03763878T
Other languages
English (en)
Inventor
Simon Bateman
Moise Azria
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE538782T1 publication Critical patent/ATE538782T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT03763878T 2002-07-17 2003-07-16 Modifizierte aminosaeure 5-cnac zur hemmung der thrombozytenaggregation ATE538782T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39689802P 2002-07-17 2002-07-17
PCT/EP2003/007739 WO2004006907A1 (en) 2002-07-17 2003-07-16 Modified amino acid for the inhibition of platelet aggregation

Publications (1)

Publication Number Publication Date
ATE538782T1 true ATE538782T1 (de) 2012-01-15

Family

ID=30116066

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03763878T ATE538782T1 (de) 2002-07-17 2003-07-16 Modifizierte aminosaeure 5-cnac zur hemmung der thrombozytenaggregation

Country Status (12)

Country Link
US (3) US20060106110A1 (de)
EP (1) EP1556027B1 (de)
JP (1) JP4541884B2 (de)
CN (1) CN1668290B (de)
AT (1) ATE538782T1 (de)
AU (1) AU2003257473A1 (de)
BR (1) BR0312712A (de)
CA (1) CA2492378C (de)
ES (1) ES2379949T3 (de)
PT (1) PT1556027E (de)
TW (1) TW200403052A (de)
WO (1) WO2004006907A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7318925B2 (en) 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
CA2535156A1 (en) 2003-08-08 2005-02-24 Abgenix, Inc. Antibodies directed to parathyroid hormone (pth) and uses thereof
EP3257949A1 (de) 2005-06-15 2017-12-20 Complete Genomics Inc. Nukleinsäureanalyse durch zufällige mischungen von nichtüberlappenden fragmenten
AU2006292337B8 (en) 2005-09-19 2013-02-07 Emisphere Technologies, Inc. Crystalline forms of the di-sodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid
CA2662853C (en) 2006-08-31 2016-07-26 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
KR101524880B1 (ko) * 2006-08-31 2015-06-01 노파르티스 아게 Ｈｇｈ를 포함하는 경구 전달용 제약 조성물
WO2009059188A1 (en) 2007-11-02 2009-05-07 Emisphere Technologies, Inc. Method of treating vitamin b12 deficiency
KR20130026429A (ko) * 2010-02-24 2013-03-13 에미스페어 테크놀로지스, 인코포레이티드 경구 ｂ12 치료요법
RU2504536C1 (ru) * 2012-08-20 2014-01-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Волгоградский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации Производное амида салициловой кислоты, обладающее антибактериальной, противогрибковой и антилизоцимной активностью

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260321A (en) * 1984-11-12 1993-11-09 Sandoz Ltd. Use of 1,4-dihydropyridine derivatives and combinations thereof with calcitonins
US5733647A (en) * 1992-11-05 1998-03-31 Polymer Innovations, Inc. Insole
US5563158A (en) * 1993-12-28 1996-10-08 The Dupont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
US5866536A (en) * 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
BR9604880A (pt) * 1995-03-31 1998-05-19 Emisphere Tech Inc Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica
JP4975201B2 (ja) * 1997-02-07 2012-07-11 エミスフェアー・テクノロジーズ・インク 化合物及び活性剤を送達するための組成物
US5773647A (en) * 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
NZ534409A (en) * 1999-04-05 2006-03-31 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents

Also Published As

Publication number Publication date
WO2004006907A1 (en) 2004-01-22
EP1556027A1 (de) 2005-07-27
CN1668290A (zh) 2005-09-14
US8664211B2 (en) 2014-03-04
CA2492378C (en) 2011-06-14
US20060106110A1 (en) 2006-05-18
CA2492378A1 (en) 2004-01-22
CN1668290B (zh) 2010-04-28
PT1556027E (pt) 2012-04-10
ES2379949T3 (es) 2012-05-07
US20120088833A1 (en) 2012-04-12
AU2003257473A1 (en) 2004-02-02
TW200403052A (en) 2004-03-01
JP4541884B2 (ja) 2010-09-08
JP2005535670A (ja) 2005-11-24
EP1556027B1 (de) 2011-12-28
US20080280817A1 (en) 2008-11-13
BR0312712A (pt) 2005-04-26

Similar Documents

Publication Publication Date Title
EA200301165A1 (ru) Лекарственное средство на основе оксикодона
EP1614676A4 (de) Verbindung zum inhibieren des in vivo-phosphortransports und arzneimittel, das dieses enthält
DK1135117T3 (da) Medikament til behandling af kronisk obstruktiv lungesygdom
EE04911B1 (et) Ühend ja farmatseutiline kompositsioon proteaasi inhibiitoritena, nende kasutamine ning meetod selle ühendi valmistamiseks
GEP20074123B (en) Amino acids with affinity for the alpha−2−delta−protein
BR9510168A (pt) Composto poliaminoácido composição forma unitária de dosagem e método par epreparar uma composição
EA200700387A1 (ru) Гидраты и полиморфы 4-[[(7r)-8-циклопентил-7-этил-5,6,7,8-тетрагидро-5-метил-6-оксо-2-птеридинил]амино]-3-метокси-n-(1-метил-4-пиперидинил)бензамида, способы их получения и их применение в качестве лекарственных средств
PT1245568E (pt) Derivados sulfonilo de aminoacidos e sua utilizacao enquanto inibidores da dipeptidil-peptidase iv (dpp iv)
DE60318159D1 (de) Pharmazeutische Salze von Lokalanästhetischen zusammen mit antiinflammatorischen Verbindungen und Verfahren zur Herstellung der Salze
BR0207883A (pt) Composições de medicamentos à base de anticolenérgicos e inibidores de pde-iv
MXPA03000510A (es) Sales estables de acido o-acetilsalicilico con aminoacidos basicos.
SE0002202D0 (sv) New peptides
EA200401227A1 (ru) Система доставки лекарства с контролируемым высвобождением, включающая правастатин
ATE538782T1 (de) Modifizierte aminosaeure 5-cnac zur hemmung der thrombozytenaggregation
ATE435657T1 (de) Therapeutische zubereitung von hochreinem fviia und verfahren zu dessen gewinnung
BRPI0410861A (pt) métodos e composições para a produção de aminoácidos
ATE402175T1 (de) 4-oxo-1-(3-substituiertesphenyl)-1,4-dihydro-1, - naphthyridin-3-carbonsäureamide alsphoshodiesterase-4-inhibitoren
HRP20050371B1 (hr) Oblik za primjenu farmaceutiski djelatnih peptida s produljenim oslobađanjem djelatnog sastojka i postupak za njihovu proizvodnju
ES2422081T3 (es) Péptido Ser-Ser-Ser-Arg y sus utilizaciones medicinales
BR0009472A (pt) Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas
EA200401303A1 (ru) Лекарственные средства, содержащие стероиды и новое антихолинергическое средство
EP4566667A3 (de) Behandlung von kardiometabolischen erkrankungen mit inhibitoren der typ i interferon signalübertragung
EA200501557A1 (ru) Новый способ синтеза (2s)-индолин-2-карбоновой кислоты и использование в синтезе периндоприла
EA200501223A1 (ru) Терапевтическая система, содержащая амоксициллин и клавулановую кислоту
NO20052807D0 (no) Fremgangsmate for fremstilling av aminosyrer